Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0399)
| Name |
Soyauxinium chloride
|
||||
|---|---|---|---|---|---|
| Drug Type |
Traditional Chinese Medicin
|
||||
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
| In total 5 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Responsed Disease | Glioblastoma | ICD-11: 2A00 | ||
| Pathway Response | Apoptosis | hsa04210 | ||
| Ferroptosis | hsa04216 | |||
| Necroptosis | hsa04217 | |||
| Cell Process | Cell ferroptosis | |||
| Cell apoptosis | ||||
| Cell necroptosis | ||||
| In Vitro Model | AML12 cells | Normal | Mus musculus | CVCL_0140 |
| U-87MG cells | Glioblastoma | Homo sapiens | CVCL_GP63 | |
| Response regulation | The prominent cytotoxic potential of soyauxinium chloride (SCHL) on a panel of 18 human and animal cancer cell lines, including MDR phenotypes. This investigated indoloquinazoline alkaloid induced apoptosis in CCRF-CEM cellsviacaspases activation, MMP alteration and increase of ROS production, and caused ferroptosis and necroptosis in glioblastoma. | |||
| Experiment 2 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Responsed Disease | Myeloid leukaemia | ICD-11: 2B33 | ||
| Pathway Response | Apoptosis | hsa04210 | ||
| Ferroptosis | hsa04216 | |||
| Necroptosis | hsa04217 | |||
| Cell Process | Cell ferroptosis | |||
| Cell apoptosis | ||||
| Cell necroptosis | ||||
| In Vitro Model | CCRF-CEM cells | T acute lymphoblastic leukemia | Homo sapiens | CVCL_0207 |
| Response regulation | The prominent cytotoxic potential of soyauxinium chloride (SCHL) on a panel of 18 human and animal cancer cell lines, including MDR phenotypes. This investigated indoloquinazoline alkaloid induced apoptosis in leukemia CCRF-CEM cells via caspases activation, MMP alteration and increase of ROS production, and caused ferroptosis and necroptosis. | |||
| Experiment 3 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Responsed Disease | Colon cancer | ICD-11: 2B90 | ||
| Pathway Response | Apoptosis | hsa04210 | ||
| Ferroptosis | hsa04216 | |||
| Necroptosis | hsa04217 | |||
| Cell Process | Cell ferroptosis | |||
| Cell apoptosis | ||||
| Cell necroptosis | ||||
| In Vitro Model | HCT 116 cells | Colon carcinoma | Homo sapiens | CVCL_0291 |
| CC531 cells | Colon adenocarcinoma | Rattus norvegicus | CVCL_0206 | |
| Response regulation | The prominent cytotoxic potential of soyauxinium chloride (SCHL) on a panel of 18 human and animal cancer cell lines, including MDR phenotypes. This investigated indoloquinazoline alkaloid induced apoptosis in CCRF-CEM cellsviacaspases activation, MMP alteration and increase of ROS production, and caused ferroptosis and necroptosis in colon cancer. | |||
| Experiment 4 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Responsed Disease | Melanoma | ICD-11: 2C30 | ||
| Pathway Response | Apoptosis | hsa04210 | ||
| Ferroptosis | hsa04216 | |||
| Necroptosis | hsa04217 | |||
| Cell Process | Cell ferroptosis | |||
| Cell apoptosis | ||||
| Cell necroptosis | ||||
| In Vitro Model | B16-F1 cells | Melanoma | Mus musculus | CVCL_0158 |
| B16-F10 cells | Melanoma | Mus musculus | CVCL_0159 | |
| A2058 cells | Amelanotic melanoma | Homo sapiens | CVCL_1059 | |
| SK-Mel 505 (Human melanoma cells) | ||||
| Ma-Mel-80a cells | Nodular melanoma | Homo sapiens | CVCL_A215 | |
| MV3 cells | Amelanotic melanoma | Homo sapiens | CVCL_W280 | |
| SK-MEL-28 cells | Cutaneous melanoma | Homo sapiens | CVCL_0526 | |
| Mel-2a cells | Melanoma | Homo sapiens | CVCL_A759 | |
| Response regulation | The prominent cytotoxic potential of soyauxinium chloride (SCHL) on a panel of 18 human and animal melanoma cancer cell lines, including MDR phenotypes. This investigated indoloquinazoline alkaloid induced apoptosis in CCRF-CEM cellsviacaspases activation, MMP alteration and increase of ROS production, and caused ferroptosis and necroptosis. | |||
| Experiment 5 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Responsed Disease | Breast cancer | ICD-11: 2C60 | ||
| Pathway Response | Apoptosis | hsa04210 | ||
| Ferroptosis | hsa04216 | |||
| Necroptosis | hsa04217 | |||
| Cell Process | Cell ferroptosis | |||
| Cell apoptosis | ||||
| Cell necroptosis | ||||
| In Vitro Model | U-87MG cells | Glioblastoma | Homo sapiens | CVCL_0022 |
| MDA-MB-231 cells | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | |
| Response regulation | The prominent cytotoxic potential of soyauxinium chloride (SCHL) on a panel of 18 human and animal cancer cell lines, including MDR phenotypes. This investigated indoloquinazoline alkaloid induced apoptosis in CCRF-CEM cellsviacaspases activation, MMP alteration and increase of ROS production, and caused ferroptosis and necroptosis in breast cancer. | |||
